A Phase 1 Study of ADI-001 in B Cell Malignancies

NCT04735471 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated - Halted Prematurely

Conditions

Lymphoma, Follicular
Lymphoma, Mantle-Cell
Marginal Zone Lymphoma
Primary Mediastinal B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Lymphoma, Non-Hodgkin

Interventions

GENETIC: ADI-001
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Adicet Therapeutics